In vitro testing of pharmaceutical aerosols and predicting lung deposition from in vitro measurements

Drug Delivery to the Lung

Volumn , Issue , 2001, Pages 105-142

  Clark, Andy ^a   Borgström, Lars ^b,c  

^a NEKTAR THERAPEUTICS   (United States)

^b ASTRAZENECA R AND D   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85034250334     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (44)

1. Clark AR, Egan MJ. Modelling the deposition of inhaled powdered drug aerosols. J Aerosol Sci. 1994:25, 1:175–186.
2. Rudolf G, Kobrich R, Stahlhofen W. Modelling and algebraic formulation of regional aerosol deposition in man. J Aerosol Sci. 1990; 21 (suppl 2):403–406.
3. Clark AR. The use of laser diffraction for the evaluation of the aerosol clouds generated by medical nebulizers. Int J Pharm 1995; 115:69–78.
4. Hinds WC. Aerosol Technology; Properties, Behavior, and Measurement of Airborne Particles. New York: Wiley, 1982.
5. Hatch T, Choate SP. Statistical Description of Size Properties of Non-Uniform Particle Substances. Franklin Institute, 1929: 207, 369.
6. Marple V, Olson BA, Miller NC. The role of inertial particle collectors in evaluating pharmaceutical aerosol delivery systems. J Aerosol Med 1998; 11(1):S139–S153.
7. Rao AK, Whitby KT. Non-ideal collection characteristics of single stage and cascade impactors. Am Ind Hyg Assoc J 1977; 38(4):174–179.
8. Nichols SC, Brown DR, Smurthwaite M. New concept for variable flow rate Andersen cascade impactor and calibration data. J Aerosol Med 1998; 11(1):S133–S138.
9. Asking L, Olsson B. Calibration of the multistage liquid impinger at different flows. Pittsburgh, PA: AAAR, 1995;185.
10. Dolovich M, Rhem R. Impact of oropharyngeal deposition on inhaled dose. J Aerosol Med 1998; 11(1): S112–SS115.
11. Felton PG, Hamidi AA, Aigai AK. Measurement of drop-size distribution in dense sprays by laser diffraction. Proceedings, ICLAS-85. Third International Conference on Liquid Atomization and Spray Systems (The Institute of Energy, London, 1985), IVA/4/1.
12. Mitchell JP, Nagel MW. Time-of-flight aerodynamic particle size analyzers: their use and limitations for the evaluation of medical aerosols. J Aerosol Med 1999: 12(4):217–240.
13. Mitchell JP, Nagel MW, Archer AD. Size analysis of a pressurized metered dose inhaler– delivered suspension formulation by API aerosizer particle size analyzer. J Aerosol Med 1999; 12(4): 255–264.
14. Clifford RH, Ishi I, Montaser A. Dual beam light-scattering interferometry for simultaneous measurements of droplet-size and velocity distributions of aerosols from commonly used nebulizers. Chemistry 1990; 62:309–394.
15. Dunhar C. An experimental investigation of the spray issued from a pMDI using laser diagnostic techniques. J Aerosol Med. 1997; 10 (4) 351–358.
16. Finlay W, Stapleton K, Zuberbuhaler P. Variations in predicted regional lung deposition of salbutamol sulphate between 19 nebulizer types. J Aerosol Med 1998; 11 (2):65–80.
17. Snell NJC, Ganderton D. Assessing lung deposition of inhaled medications. Respir Med 1999; 93:123–133.
18. Perring S, Summers QA, Fleming JS, Nassim MA, Holgate ST. A new method of quantification of pulmonary regional distribution of aerosols using combined CT and SPECT and its application to nedocromil sodium administered by metered dose inhaler. Br J Radiol 1994; 67:46–53.
19. Newman SP, Morén F, Trofast E, Talace N, Clarke SW. Deposition and clinical efficacy of terbutaline sulphate from Turbuhaler, a new multi-dose powder inhaler. Eur Respir J 1989; 2:247–252.
20. Smaldone G, Perry R J, Bennett W D, Messina M S, Zwang J, Ilowite J. Interpretation of “24 hour lung retention” in studies of mucociliary clearance. J Aerosol Med 1988; 1:11–20.
21. Agnew JE, Lopez-Vidriero MT, Pavia D, Clarke SW. Functional small airways defense in symptomless cigarette smokers. Thorax 1986; 41:524–530.
22. Newman SP, Hirst PII, Pitcairn GR, Clark AR. Understanding regional lung deposition data in gamma scintigraphy. In: Respiratory Drug Delivery VI. Hilton Head, SC, 1998:19–26.
23. International Commission on Radiological Protection. Human respiratory tract model for radiological protection. 1994. ICRP Publication 66. Ann ICRP, 24, nos 1–3.
24. Borgström L, Nilsson M. A method for determination of the absolute bioavailability of inhaled drugs. Pharm Res 1990; 7:1068.
25. Richards R, Dickson C, Renwick A, Lewis R, Holgate S. Absorption and disposition kinetics of cromolyn sodium and the influence of inhalation technique. J Pharmacol Exp Ther 1987; 241(3): 1028–1032.
26. Biddiscombe M. The radiolabelling of salbutamol with technetium-99m and its application to the study of salbutamol deposition in the human respiratory tract. Ph. D. thesis, University of London, 1994.
27. Borgström L, Newman S P, Weisz AA, Moren F. Pulmonary deposition of inhaled terbutaline: Comparison of scanning gamma camera and urinary excretion methods. J Pharm Sci 1995; 81:753–755.
28. Finlay WH, Stapleton KW. The effect on regional lung deposition of coupled heat and mass transfer between hygroscopic droplets and their surrounding phase. J Aerosol Sci 1995; 26:655–670.
29. Portstendörfer J, Gebhart J, Robig G. Effect of evaporation on the size distribution of nebulized aerosols. J Aerosol Sci 1977; 8:371–380.
30. Smaldone GC, Diot P, Groth M, Ilowite J. Respirable mass: vague and indefinable in disease. J Aerosol Med 1998; 11(1): S105–S111.
31. Finlay W, Stapleton K. Undersizing of droplets from a vented nebulizer caused by aerosol heating during transit through an Anderson impactor. J Aerosol Sci 1999; 30(1): 105–109.
32. Clark AR. MDIs: physics of aerosol formation. J Aerosol Med 1996: 9(suppl 1): S19.
33. Clark AR. Medical aerosol inhalers: past, present, and future. Aerosol Sci Tech 1995; 22: 374–391.
34. Clark A, Hollingworth A. The relationship between powder inhaler resistance and peak inspiratory conditions in healthy volunteers—implications for in vitro testing. J Aerosol Med 1993; 6(2):99–110.
35. Price A, Rowland M, Aarons L, Pritchard J, Falcoz C. The use of LUDEP, as a tool, in the prediction of total and regional deposition: advantages, limitations and possible developments of the package. In: Drug Delivery to the Lungs IX, The Aerosol Society, 1998:51–55.
36. Newman S. P. How well do in vitro particle size measurements predict drug delivery in vitro. J Aerosol Med 1998; 11(1):S97–S103.
37. Olsson B. Borgström L, Asking L, Bondesson E. Effect of inlet throat on the correlation between measured fine particle dose and lung deposition. In: Respiratory Drug Delivery V. Phoenix AZ: 1996.
38. Swift DL. The oral airway—a conduit or collector for pharmaceutical aerosols? In: Respiratory Drug Delivery IV. Richmond, VA: 1994.
39. Thiel CG. Can in vitro particle size measurements be used to predict pulmonary deposition of aerosol from inhalers? J Aerosol Med 1998; 11(1):S43–S51.
40. Clark AR, Newman SP, Dasovich N. Mouth and oropharyngeal deposition of pharmaceutical aerosols. J Aerosol Med 1998; 11(1):S116–S121.
41. Pritchard J, Burnell P. Interpretation of in vitro particle size data from dry powder inhalers. In: Respiratory Drug Delivery VI. Hilton Head, SC, 1998: 401–404.
42. Pritchard J, Layzell G, Miller J. Correlation of cascade impactor data with measurements of lung deposition for pharmaceutical aerosols. In: Drug Delivery to the Lungs VII, The Aerosol Society, 1996: 101–104.
43. Borgström L, Asking L, Beekman O, Bondesson E, Kallen A, Olsson B. Discrepancy between in vitro and in vivo variability for a pressurized metered dose inhaler and a dry powder inhaler. J Aerosol Med 1998; 11(1):S59–S64.
44. Melchor R, Biddiscombe M, Mak V, Short M, Spiro S. Lung deposition patterns of directly labelled salbutamol in normal subjects and in patients with reversible airflow obstruction. Thorax 1993; 48:506–511.